Palvella Therapeutics Inc.

Contributing Author

Recent Articles by Palvella Therapeutics Inc.

Mar-10	Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations PVLA GlobeNewswire
Mar-02	Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PVLA GlobeNewswire
Feb-25	Palvella Therapeutics Announces Pricing of Upsized Public Offering PVLA +15.35% GlobeNewswire
Feb-24	Palvella Therapeutics Announces Proposed Public Offering PVLA +37.08% GlobeNewswire
Feb-24	Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations PVLA +37.08% GlobeNewswire
Feb-23	Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations PVLA GlobeNewswire
Feb-02	Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis PVLA GlobeNewswire
Jan-09	Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies PVLA -5.10% GlobeNewswire
Jan-07	Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs PVLA +11.72% GlobeNewswire
Dec-16	Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas PVLA +8.80% GlobeNewswire
Dec-15	Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies PVLA -9.74% GlobeNewswire
Nov-11	Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
Nov-06	Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference PVLA GlobeNewswire
Nov-05	Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies PVLA GlobeNewswire
Nov-04	Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 PVLA GlobeNewswire
Oct-13	U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA +9.04% GlobeNewswire
Sep-24	Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies PVLA GlobeNewswire
Sep-17	Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy PVLA GlobeNewswire
Sep-15	Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations PVLA GlobeNewswire
Sep-03	Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer PVLA GlobeNewswire
Aug-28	Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences PVLA -9.12% GlobeNewswire
Aug-14	Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
Aug-07	Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 PVLA GlobeNewswire
Aug-05	Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference PVLA GlobeNewswire
Jun-30	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes PVLA GlobeNewswire
Jun-23	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% PVLA GlobeNewswire
Jun-18	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors PVLA GlobeNewswire
Jun-09	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
May-27	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer PVLA GlobeNewswire
May-15	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
May-08	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 PVLA GlobeNewswire
May-05	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 PVLA GlobeNewswire

Palvella Therapeutics Inc.

Recent Articles by Palvella Therapeutics Inc.

Upgrade your FINVIZ experience